Glucocorticoids and CBG during pregnancy in mammals: diversity, pattern, and function.

Pregnancy is one of the defining characteristics of placental mammals. Key in the growth and development of the fetus during pregnancy are the dynamics of glucocorticoids (GCs) and their binding protein,corticosteroid-binding globulin (CBG), which determines how much of the GCs are free and biologically active. Out of more than 5000 species of placental mammals in 19 different orders, our understanding of the dynamics of maternal GCs and CBG during pregnancy is largely limited to the detailed study of 3 groups - sheep, laboratory rodents, and humans. The assumption is often made that what we see in these few species applies to the rest. To examine this generality, we compared patterns of maternal GCs over pregnancy from all placental mammals where data is available: in the blood of 13 species from 5 different orders and in metabolites in excreta in an additional 20 species from 9 orders. We found that maternal free GCs increase by late pregnancy in most taxa. This increase is achieved by either an increase in total GC secretion or a decrease in CBG. A major exception is found in the even-toed ungulates (sheep, cows, etc.) where maternal GCs and CBG remain stable, but where the fetal adrenals mature in late pregnancy and produce the majority of their own GCs. We conclude that patterns of change in maternal GCs and CBG during pregnancy are species-specific but are alternative means to the same end: increased fetal exposure to GCs in late pregnancy, which is essential for development.

Chronic stress does not further exacerbate the abnormal psychoneuroendocrine phenotype of Cbg-deficient male mice.

Chronic stress leads to a dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis which can constitute a base for pathophysiological consequences. Using mice totally deficient in Corticosteroid binding globulin (CBG), we have previously demonstrated the important role of CBG in eliciting an adequate response to an acute stressor. Here, we have studied its role in chronic stress situations. We have submitted Cbg ko and wild-type (WT) male mice to two different chronic stress paradigms - the unpredictable chronic mild stress and the social defeat. Then, their impact on neuroendocrine function - through corticosterone and CBG measurement - and behavioral responses - via anxiety and despair-like behavioral tests - was evaluated. Both chronic stress paradigms increased the display of despair-like behavior in WT mice, while that from Cbg ko mice - which was already high - was not aggravated. We have also found that control and defeated (stressed) Cbg ko mice show no difference in the social interaction test, while defeated WT mice reduce their interaction time when compared to unstressed WT mice. Interestingly, the same pattern was observed for corticosterone levels, where both chronic stress paradigms lowered the corticosterone levels of WT mice, while those from Cbg ko mice remained low and unaltered. Plasma CBG binding capacity remained unaltered in WT mice regardless of the stress paradigm. Through the use of the Cbg ko mice, which only differs genetically from WT mice by the absence of CBG, we demonstrated that CBG is crucial in modulating the effects of stress on plasma corticosterone levels and consequently on behavior. In conclusion, individuals with CBG deficiency, whether genetically or environmentally-induced, are vulnerable to acute stress but do not have their abnormal psychoneuroendocrine phenotype further affected by chronic stress.

Enhanced Activity of Topical Hydrocortisone by Competitive Binding of Corticosteroid-Binding Globulin.

Atopic dermatitis of sensitive areas such as the face, particularly in children, is a difficult disease to treat as the standard therapeutic, topical steroids, is contraindicated for this application in children. Hydrocortisone (HC) can be used in these instances because it has been shown to be safe, but is often ineffective as it is a relatively weak steroid, especially at over-the-counter concentrations. To enhance the local topical activity of HC, the terminal inactive metabolite of prednisolone, Δ(1)-cortienic acid (Δ(1)-CA), is added to HC, as Δ(1)-CA preferentially binds transcortin, liberating more HC to elicit its therapeutic effect. Skin blanching studies, which are used to evaluate the potency of topical steroids, were employed to assess the ability of Δ(1)-CA to enhance the activity of HC. The results demonstrate that Δ(1)-CA, when applied in combination with HC, does indeed potentiate the vasoconstriction effect of topically applied HC, while having no effect alone. Thus, addition of the inert prednisolone metabolite Δ(1)-CA can increase the therapeutic effect of over-the-counter concentrations of HC when applied topically.

Inhibition of endogenous RNA polymerase activity from thymus chromatin by transcortin-hydrocortisone complex.

A transortin-hydrocortisone complex has been isolated from human serum by affinity chromatography on oxidized corticosterone coupled to AH-Sepharose 4B. The influence of this complex and of hydrocortisone alone on endogenous RNA polymerase activity from thymus chromatin have been tested. Results show that hydrocortisone alone has no effect on RNA polymerase activity from thymus chromatin. Under the same experimental conditions, The transcortin-hydrocortisone complex induces an important decrease in the incorporation of UMP into RNA. The dose response of thymic RNA polymerase to transcortin-hydrocortisone complex and the effects of alpha-amanitin on this response are also reported.

The effect of corticosteroid-binding globulin on the in vitro incorporation of thymidine into human lymphocytes.

The purpose of these studies was to examine the inhibitory effect of human corticosteroid-binding globulin (CBG) on the mitogenic effect of phytohemagglutinin on cultured human lymphocytes. We found that CBG could inhibit the incorporation of [14C] thymidine into lymphocytes, but the observed inhibition could be accounted for by the cortisol which was bound to the purified CBG, CBG stripped of cortisol or bound to 11-deoxycortisol was inactive in this assay.

The effect of cortisol, progesterone, and transcortin on phytohemagglutinin-stimulated human blood mononuclear cells and their interplay.

The effect of transcortin on [3H]thymidine incorporation into phytohemagglutinin-stimulated human peripheral blood mononuclear cells and its influence on the well known suppressive effect of cortisol were investigated. Human transcortin by itself had no effect on thymidine incorporation between the concentrations of 0.25-1 X 10(-6) M. When transcortin was added to cortisol, the suppressive effect of cortisol decreased in proportion to the decrease in the protein-unbound cortisol concentration. We also investigated the influence of progesterone on transcortin-bound cortisol. When 0.5 and 1 X 10(-6) M transcortin, which contained 1 and 2 X 10(-7) M cortisol as a transcortin-bound form, were added to 5 X 10(-6) M progesterone, greater suppression of thymidine incorporation was observed that than produced by progesterone alone (86.1% and 81.3 for 0.5 and 1 X 10(-6) M transcortin, respectively). Moreover, when 5 X 10(-7) M transcortin containing the same amount of cortisol was added with 1, 2, and 5 X 10(-6) M progesterone, a greater suppression (92.6%, 74.1%, and 32.4% of control for 1, 2, and 5 x 10(-6) M progesterone) was demonstrated than that caused by progesterone alone (95.1%, 75.8%, and 49.5% of control for the corresponding concentrations of progesterone). This increased suppression was accompanied by an increase in the percentage of protein-unbound cortisol. These results indicate that unbound cortisol, whose concentration increases in the presence of progesterone, may be biologically active. The interaction between progesterone and cortisol may be modulated in part by the transcortin concentration.

Corticosteroid-binding globulin (CBG) production by hepatic and extra-hepatic sites in the ovine fetus; effects of CBG on glucocorticoid negative feedback on pituitary cells in vitro.

Plasma cortisol levels increase in fetal sheep during late gestation and this is associated with an increase in plasma corticosteroid-binding globulin (CBG) concentrations. However, the relative tissue sources of plasma CBG, the ontogeny of its biosynthesis and glycoform composition have not been established in the ovine fetus. Therefore we examined whether changes in plasma corticosteroid binding capacity (CBC) in fetal sheep during late gestation were associated with different patterns of glycosylation and reflected changes in tissue CBG expression. Since free cortisol is considered the bioactive fraction, we measured changes in the percent and absolute free cortisol in fetal plasma during late gestation. In order to examine whether CBG alters cortisol negative feedback at the level of the fetal pituitary, we also examined the effect of exogenous CBG in mediating the glucocorticoid-induced suppression of basal and corticotrophin-releasing hormone (CRH)-stimulated ACTH release from fetal pituitary cells in culture. The mean free cortisol concentration in plasma was not different between days 15 and 20 prior to parturition, and between 5 and 10 days prepartum, although it did rise between these times. Plasma CBC in chronically catheterized fetuses rose from 23.3 +/- 4.6 ng/ml at day 115 to 86.5 +/- 20.8 ng/ml at term and then decreased rapidly after birth. Between day 125 and day 140 of pregnancy approximately 10% of fetal plasma CBG was retarded by Concanavalin-A chromatography. This proportion increased at birth and attained adult values of > 70% by one month of age. By Northern blotting the relative levels of CBG mRNA in the fetal liver did not change between days 100 and 125, then increased significantly at day 140, but declined at term and in newborn lambs. CBG mRNA was undetectable in total RNA from lung, kidney, hypothalamus and placentomes, but was present in the fetal pituitary at days 125 and 140. Reverse transcription-PCR was used to confirm the presence of CBG mRNA in pituitary tissue from term fetuses. In cultures of term fetal pituitary cells, added CBG attenuated the cortisol- but not the dexamethasone-mediated suppression of basal and CRH-stimulated ACTH release. We conclude that in fetal sheep there is an increase in the corticosteroid binding capacity of plasma during late pregnancy which regulates, in part, free cortisol levels in the circulation. The liver is the major site of CBG biosynthesis in the fetus and at least until day 140 of gestation the rise in plasma CBC is associated with an increase in hepatic CBG mRNA levels.(ABSTRACT TRUNCATED AT 400 WORDS)

Three-dimensional molecular descriptors and a novel QSAR method.

A novel set of molecular descriptors suitable for use in quantitative structure-activity relationships and related methods is described. These descriptors are a smooth and interpretable representation of atomic physicochemical property values and intramolecular atom pair distances. Distance atomic physicochemical parameter energy relationships (DAPPER), a novel structure-activity relationship (QSAR) method using these descriptors, is validated on standard datasets.

Progesterone sperm chemoattraction may be modulated by its corticosteroid-binding globulin carrier protein.

Progesterone, the main steroidal component secreted by the cumulus cells that surround the egg, chemotactically guides human spermatozoa. The aim of this work was to evaluate whether the carrier protein corticosteroid-binding globulin also participates in the sperm P chemotactic response. By means of videomicroscopy and image analysis, we observed that corticosteroid-binding globulin modulates the chemotactic activity of P, when a solution of corticosteroid-binding globulin + P is at the nanomolar range.

Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats.

PURPOSE: The effect of exogenous corticosteroid binding globulin (CBG) on the pharmacokinetics of intravenous prednisolone was determined in rats to test the "free hormone hypothesis." METHODS: A dose of CBG to yield 95% binding with 1000 ng/ml of prednisolone in vitro in rat plasma or saline was administered before dosing 2 mg/kg of prednisolone hemisuccinate or methylprednisolone intravenously. Drug concentrations in plasma samples were assayed by HPLC. RESULTS: Single administration of CBG decreased apparent prednisolone clearance by 56% (155 to 66 ml/min/kg) and reduced apparent VSS by 35% (4.1 to 2.7 L/kg) (p < 0.001). Methylprednisolone pharmacokinetics, studied as a negative control because the drug does not bind to CBG, did not change. CONCLUSIONS: The corticosteroid bound to CBG does not appear to be available for removal by clearance organs.

The effects of CBG on the in vitro reduction of 3H-progesterone by liver homogenates and cell suspensions.

The effects of CBG on 3H-progesterone metabolism by ovine, bovine and rat liver homogenates and bovine and rat liver cell suspensions were studied. As a source of CBG served plasma from "estrogenized" women. Same plasma, pretreated at 60 degree for 20 min. served as control. It was found that the amounts of 3H-progesterone remaining after incubation were higher in the presence of CBG, as compared with control incubations, when using the homogenates. No such effect was observed in case of cell suspensions.

CBG does not restrict blood-brain barrier corticosterone transport in rabbits.

The metabolic clearance rate of corticosterone in rabbits is unrelated to the physiological concentration of corticosteroid binding globulin (CBG) in rabbit plasma. This suggests that corticosterone is available for transport into peripheral tissues in rabbits from the circulating CBG-bound pool, similar to what is known to occur in rat liver. This hypothesis was tested in the present studies, which investigate the transport of corticosterone into rabbit brain from the circulating rabbit or human CBG-bound pool. Corticosterone was readily exchangeable in brain capillaries in vivo from the circulating albumin-bound and rabbit or human CBG-bound pools. The involvement of specific CBG receptors on brain capillary endothelia in this process was investigated with [3H]-labeled human CBG prepared by reductive methylation. The transport of [3H]CBG across rabbit brain capillaries in vivo was immeasurably low, and no specific binding of this radiolabeled plasma protein to isolated brain capillaries in vitro was observed at 37 degrees C during incubations up to 120 min. These studies indicate that the rabbit is a novel system for assessing the role of CBG in delivering corticosterone to peripheral tissues in vivo and that specific endothelial CBG receptors may not participate in the transport process.